TECH · Q2 2026 Earnings

Cautious

Bio-Techne

Reported February 4, 2026

30-second summary

Bio-Techne's Q2 FY2026 print delivered flat organic growth ($295.9M reported, 0% organic, +2% FX tailwind) — better than the trajectory implied by Q1 commentary but still flat at the headline. Adjusted operating margin reached 31.1%, up 100bps YoY, and management reaffirmed the FY2026 +100bps walk while quantifying for the first time a specific 300bps Q3 cell therapy headwind. The "underlying growth" framing got sharper — 3% ex-cell-therapy and ex-OEM in Q2, with mid-single-digit guided for Q3 ex-headwinds — but the headline trajectory now requires Q4 to do nearly all the FY math, and management's "customer sentiment improving as we progress through calendar 2026" is the new soft anchor where a numerical FY guide should be.

Headline numbers

EPS

Q2 FY2026

$0.46

Revenue

Q2 FY2026

$0.30B

+0.0% YoY

Gross margin

Q2 FY2026

64.6%

Operating margin

Q2 FY2026

18.4%

Key financials

Q2 FY2026

Metric	Q2 FY2026	YoY	Q1 FY2026	QoQ
Revenue	$0.30B	+0.0%	$0.29B	+3.2%
EPS	$0.46	—	$0.42	+9.5%
Gross margin	64.6%	—	65.6%	-100bps
Operating margin	18.4%	—	16.6%	+180bps

Guidance

Company maintains full-year margin expansion guidance of 100 bps while acknowledging persistent headwinds: Q2 saw flat organic growth, Q3 expected to match, but underlying business (ex-cell therapy/OEM) guided to mid-single-digit growth.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Organic revenue growth	Q2 FY2026	not explicitly quantified	0.0%	in-line with qualitative expectations	Met

New guidance

Metric	Period	Guide	YoY
Organic revenue growth	Q3 FY2026	consistent with Q2 (flat)	—
Organic revenue growth (excluding cell therapy and OEM headwinds)	Q3 FY2026	mid-single digits	—
Cell therapy customer headwind impact	Q3 FY2026	approximately 300 basis points year-over-year	—

Reaffirmed unchanged this quarter: Operating margin expansion (100 basis points)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
Protein Sciences	$0.215B	+2.0%
Diagnostics and Spatial Biology	$0.081B	-4.0%
Protein Sciences Organic Revenue Growth	-1.0%	—
Diagnostics and Spatial Biology Organic Revenue Growth	3.0%	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026
Adjusted Operating Margin	31.1%
Protein Sciences Operating Margin	39.3%
Diagnostics and Spatial Biology Operating Margin	10.4%
Organic Revenue Growth	0.0%
Foreign Currency Impact	+2.0% favorable
Large Pharma End Market Growth	Double-digit for fourth consecutive quarter

Management tone

Narrative arc: Until headwinds subside (Q4 FY2025) → Encouraging signs of stabilization (Q1 FY2026) → Underlying growth ex-headwinds (Q2 FY2026)

The "underlying growth ex-headwinds" frame has hardened from a one-off Q&A bridge into the primary management lens. In Q4 FY2025 the company retired the double-digit narrative; in Q1 the "ex-two-customers" math appeared in Q&A as a bridge to defend the FY guide; this quarter management led with it in prepared remarks: "in our fiscal Q1, our underlying organic growth, excluding the largest cell therapy customers, was 1%. In Q2, the underlying growth was 3%, when also backing out the favorable timing of the Protein Sciences OEM customer supply order." The shift signals management has concluded the headline organic number will not improve enough in H2 to carry the story alone — the ex-headwind frame is now the durable lens through FY2027.

Cell therapy headwind sizing got specific in a way it had not before. Q1 quantified Q1/Q2 impacts (200bps / 400bps) in Q&A; this quarter management quantified Q3 (300bps) in prepared remarks and committed to "moderating further in our fourth quarter and then being completely out of our year-over-year comparisons in fiscal 2027." The granular forward sizing reads as management trying to put a fence around the drag — useful if it holds, but it also implicitly acknowledges that the air pocket is wider than the Q4 FY2025 framing ("trough quarter ahead, recovery visible") implied. Two quarters ago this was a transient comp issue; today it is a four-quarter event with a defined exit.

Stabilization language is being replaced by "customer sentiment improving through calendar 2026." Q1 anchored to "encouraging signs of stabilization." This quarter Hippel reframed forward: "customer sentiment should be gradually improving as we progress through the calendar year 2026." The shift from present-tense stabilization to future-tense sentiment improvement pushes the inflection further out — and "sentiment" is a softer claim than the order- or funding-based stabilization signals of Q1. This is the third consecutive quarter where the recovery moves one quarter further to the right.

Margin conviction reframed away from the "+200bps Q4 exit." The Q4 FY2025 setup explicitly guided to "+100bps FY with Q4 exiting at +200bps." This quarter the framing collapsed to just "+100bps for the full year" with the H2 ramp now described as half-from-gross-margin-mix-unwind, half-from-revenue-leverage. The Q4 exit number is gone from the script. Q2 op margin of 31.1% (+100bps YoY) is consistent with the full-year walk, but the back-half exit rate has been quietly softened.

Wilson-Wolf timeline reaffirmed but framed by founder caution. In Q1, founder John Wilson "still believes he can hit EBITDA targets but conditions make it tougher." This quarter Wilson-Wolf grew 20% with 70%+ EBITDA margins and the calendar 2027 close timeline was reaffirmed. The improving Wilson-Wolf trajectory is one of the few unambiguously positive shifts versus prior quarters.

Recurring themes management leaned on this quarter:

Stabilization of end markets with gradual improvement trajectoryStrategic growth verticals (cell therapy, proteomics, spatial biology, diagnostics) now 47% of revenue, delivering upper-teens CAGROperating margin expansion (100 bps YoY) driven by cost discipline and favorable operating leverageTemporary customer-specific headwinds masking underlying mid-single-digit growth momentumGeographic divergence: China and APAC accelerating (~20% APAC growth) while Americas soft, EMEA flatInnovation delivery (LEO fluorescence, ultra-sensitive ELA assays, Coltrex synthetic hydrogel) maintaining competitive positioning

Risks management surfaced:

Unfavorable product and customer mix pressuring gross margins (70.5% to 68.5% YoY)Emerging biotech customers still facing funding pressures despite H2 2025 reboundCell therapy GMP reagent demand suppressed by FDA fast-track designation pace-of-trial dynamics (~30% decline in cell therapy revenue)U.S. academic funding still challenged despite improved appropriations outlook (low single-digit decline)Large OEM customer orders timing volatility (Q2 pull-forward creating Q3 headwind)

Q&A highlights

Patrick Donnelly · Citigroup

Clarification on mid-single-digit underlying growth guidance for FY26, biotech customer timing of recovery relative to funding improvements, and sizing of GMP business impact from two fast-track cell therapy customers at peak vs. normalized levels.

Management confirmed mid-single-digit baseline growth excluding customers, explained six-month typical lag (±1 quarter) from funding to tool spending with faster reagent pull-through and slower CapEx. Detailed that two GMP customers represented 40% of GMP business at peak, created 200-400 basis point headwinds in Q1-Q2, with 300 and 100-200 basis point impacts expected for Q3-Q4. Underlying GMP growth was 30% last quarter and is expected to normalize to that rate post-reset in FY27.

Mid-single-digit underlying growth baseline FY26Six-month funding-to-spending lag, ±one quarterTwo GMP customers = 40% of GMP business at peak200 bps headwind Q1, 400 bps Q2, 300 bps Q3, 100-200 bps Q4

Dan Arias · Stifel

Clarification on whether mid-single-digit Q4 guidance assumes improvement in academic/biotech or relies on pharma strength and GMP normalization. Follow-up on Luna 4 spatial consumables pull-through trajectory and timing of improvement toward 90K target.

Management stated mid-single-digit Q4 growth achievable largely without academic/biotech improvement due to easier comps, but significant spending improvements in those channels would be upside. On spatial, noted academic mix shifted favorably toward oncology and neurology (spatial's preferred tools), consumables returned to positive growth despite market pressure. Current pull-through is 45K per instrument per year, targeting 90K long-term through multi-omics adoption. Expects trend improvement quarter-by-quarter in 2026 but characterized as multi-quarter or longer adoption play.

Current Luna 4 pull-through: 45K per instrument per yearTarget pull-through: 90K per instrument per yearAcademic market stabilized, mix shifted to oncology and neurologySpatial consumables returned to positive growth in constrained markets

Brandon Couillard · Wells Fargo

Explanation of operating margin outperformance in H1 despite adverse mix, and reconciliation of maintaining 100 bps FY expansion guidance vs. prior 200 bps exit rate commentary. Operating cash flow decline in H1 and full-year guidance.

Management attributed H1 margin outperformance to timing and flagged Q3/Q4 dynamics: Q3 as tougher comp, Q4 as easier comp. Half of sequential H2 expansion expected from gross margin improvement as negative mix unwinds, other half from higher revenue. Full-year remains 100 bps operating margin expansion. H1 cash flow weakness primarily Q1-driven: bonus payout timing (lower payouts last year vs. normal payout this year) and tax payment timing. Tax timing to unwind throughout year, but bonus timing differential permanent for FY.

H1 operating margin expansion outperforming on timingFull-year operating margin expansion: 100 basis pointsQ2 2025 cash flow on par with prior yearQ1 cash flow impacted by higher bonus payouts (timing differential vs. prior year)

Mac Italk · Stevens, Inc.

Update on organoid market interest and revenue contribution, and M&A strategy including valuation and pipeline focus areas.

Organoid business described as $50 million run-rate, part of $1.4 billion market growing mid-teens. Management highlighted synergies across multiple divisions (cell therapy, spatial biology, protein analysis). Recently launched Coltrex animal-free synthetic hydrogel for organoid growth. On M&A, stated core interests in novel antibodies, cell therapy portfolio broadening, and proteomic analysis. Wilson Wolf acquisition 20%-owned, will be finalized by end of calendar 2027 (within 8 quarters). Wilson Wolf grew 20% last quarter with 70%+ EBITDA margins. Management expressed interest in additional acquisitions between now and Wilson Wolf close.

Organoid business: $50 million run-rateOrganoid market: $1.4 billion, growing mid-teensWilson Wolf ownership: 20%, finalized by end of calendar 2027Wilson Wolf growth: 20% last quarter

Answers to last quarter's watch list

Q2 organic at "~1% minus 400bps headwind" trajectory (i.e. ex-cell-therapy ~+3%) — Q2 reported organic landed at 0%, better than the trajectory implied by Q1's framing. The cell therapy headwind came in lighter than 400bps and an OEM order pulled forward. Ex-cell-therapy and ex-OEM, underlying growth was 3% — confirming the Q1 bridge math. Status: Resolved positively

Protein Sciences adj. op margin at or above 38.4% — Q2 Protein Sciences op margin was 39.3%, up 90bps from Q1 but down 190bps from the prior-year 41.2%. The watch was that further YoY step-down would pressure the FY +100bps walk; the YoY step-down did occur, though sequential recovery offset some of the concern. Status: Mixed — sequentially better, YoY pressure persists

Biotech funding recovery translating to orders — Management cited "sequential improvement" in emerging biotech demand and called out the H2 2025 funding rebound as positioning the segment for improvement going forward, but did not point to specific order acceleration this quarter. Donnelly Q&A established a six-month funding-to-spending lag with ±1 quarter dispersion, implying meaningful order translation lands in Q4/H1 FY2027. Status: Continue monitoring

Spatial Biology organic disclosure with a +5% threshold — Management did not break out Spatial Biology organic growth as a standalone number. Combined D&SB organic held at +3%; spatial consumables "returned to positive growth"; Luna 4 pull-through remains $45K vs. the $90K long-term target. The "early signs of accelerating growth" claim from Q1 was not reinforced with a quantified spatial print this quarter. Status: Not resolved

Numerical FY2026 guidance introduction — Management again declined to provide a numerical FY range, holding to "low single digits" qualitatively and adding the new 300bps Q3 cell therapy quantification only at the headwind level. Third consecutive quarter without a numerical FY guide. Status: Resolved negatively

What to watch into next quarter

Whether Q3 organic lands at flat (the new guide) or slips negative — the 300bps cell therapy headwind plus the unwind of the Q2 OEM pull-forward suggests a soft setup. A Q3 print below -1% reported organic would imply ex-headwind underlying growth is below the mid-single-digit guide, and the FY low-single-digit posture becomes unworkable without a Q4 spike.

Protein Sciences op margin trajectory against the tough YoY comp — segment margin was down 190bps YoY in Q2 (39.3% vs. 41.2%). Watch whether Q3 sustains the 90bps sequential recovery pace or stalls; further YoY erosion of the magnitude seen in Q2 would suggest the OEM mix unwind is more damaging than management's "gradual improvement through Q3 and Q4" framing implies.

Spatial Biology standalone organic growth disclosure — management declined to break it out for the second consecutive quarter despite citing "consumables returned to positive growth." A continued refusal to provide a standalone print, or a number below +5%, would confirm the "accelerating growth" claim is qualitative cover.

Whether the FY +100bps margin walk holds against the tougher Q3 YoY comp — Hippel flagged that prior-year Q3 adjusted op margin jumped to nearly 35% (from ~30% in Q2 FY2025), making Q3 FY2026 the toughest YoY comp of the year. Watch whether Q3 op margin holds in the 33-35% range or whether management quietly trims the FY walk to "approximately 100bps."

GMP business underlying growth normalization — management said underlying GMP grew 30% last quarter and expects that rate to resume post-reset in FY27. Q3's headwind moderating to 300bps (vs. 400bps in Q2) is the first test of that normalization claim — a smaller moderation would push the FY27 reset framing out further.

Sources

Bio-Techne Q2 FY2026 press release, filed 2026-02-04 (SEC EDGAR, tech-20260204xex99d1.htm)
Bio-Techne Q2 FY2026 earnings call — prepared remarks and Q&A (CEO Kim Kelderman, CFO Jim Hippel; analyst exchanges with Citigroup, Stifel, Wells Fargo, Stephens)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.